Key Highlights

  • Cash, equivalents and restricted cash reached USD 100.4 million on June 30, 2026, up from USD 18.9 million on December 31, 2025, following a convertible note sale.
  • The second quarter loss widened to USD 24.9 million from USD 14.7 million a year earlier, while the six-month loss rose to USD 44.1 million from USD 30.1 million.
  • OCU400 Phase 3 enrollment is complete, with topline data expected in the first quarter of 2027 and a Biologics license application targeted for the second quarter of 2027.
  • A published quote placed the shares at USD 0.80, up 7.57%, across 2.766 million shares traded, a snapshot whose date is unconfirmed; 339.0 million shares were outstanding at June 30, 2026.

Convertible Note Rebuilds the Cash Balance

Operating as Ocugen (NASDAQ:OCGN), the company works on gene therapies aimed at severe eye conditions. On May 5, 2026 it priced USD 115 million of 6.75% convertible senior notes due May 15, 2034 at 90% of principal, producing net proceeds near USD 99.5 million. Roughly USD 32.7 million went to repay an existing loan. The initial conversion price is about USD 2.68, a 45% premium to the USD 1.85 close on May 4. Conversion is barred before the earlier of May 15, 2027 or a defined share-reservation date. The first interest payment falls on November 15, 2026, and 6.75% on USD 115 million comes to about USD 7.8 million a year, simple arithmetic. The second quarter deck carries the note at USD 116.1 million.

Three Programs, a Shifted Timeline and Roughly 4.5 Quarters of Runway

Under the second quarter Business update, OCU400 targets retinitis pigmentosa, with topline results due in the first quarter of 2027 and a BLA set for the second quarter of 2027. OCU410ST, aimed at Stargardt disease, has an interim analysis scheduled for the third quarter of 2026 with a BLA around mid-2027, and OCU410 for geographic atrophy plans to start Phase 3 in the third quarter of 2026. The stated goal is three BLAs by 2028. With USD 100.4 million on hand and a first-half loss of USD 44.1 million, the runway works out to roughly 4.5 quarters at the recent loss pace, a rough calculation that leaves out non-cash items. Roots Pharmaceutical has agreed on a binding term sheet that could bring up to USD 255 million, plus 22% royalties.

Penny Stock Pricing, Dilution and the Missing Nasdaq Notice

At USD 0.80, Ocugen (NASDAQ:OCGN) trades as a penny stock, where thin Liquidity means a small number of trades can move the price and spreads can be wide. The 7.57% quoted gain can reverse, and nothing here suggests it will continue. Nasdaq rules allow a minimum bid notice once shares close below USD 1 for 30 consecutive business days, and no such notice appeared in the filings reviewed. Shares outstanding climbed from 312.4 million to 339.0 million in six months, so dilution is ongoing. Conversion of the notes could add up to about 62.2 million shares initially. Market Capitalization was not verified, and no third quarter report date was confirmed.

Where Things Stand

Mainly because the business has no product Revenue yet, not because it lacks near-term funding. Ocugen (NASDAQ:OCGN) held USD 100.4 million of cash at June 30, 2026, carries a USD 116.1 million convertible note, and has about 4.5 quarters of coverage at current losses by simple arithmetic. Next catalysts include the OCU410ST interim analysis in the third quarter of 2026, OCU400 topline data in early 2027 and the first note interest payment on November 15. As a penny stock, quoted prices can reverse quickly.